Bacillus calmette-guerin substrain tice live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bacillus calmette-guerin substrain tice live antigen
Accession Number
DB10343
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Description

Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.

Synonyms
  • BCG, Live, Tice Strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bcg VaccineInjection, powder, lyophilized, for solution50 mg/1PercutaneousOrganon1989-06-21Not applicableUs
OncoticePowder, for solution800000000 unitIntravesicalMerck Ltd.1995-12-31Not applicableCanada
Tice BcgPowder, for suspension50 mg/50mLIntravesicalOrganon USA Inc.1990-08-24Not applicableUs
Categories
UNII
2XQ558L16Z
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with 2-Methoxyethanol.
2-MethoxyethanolThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with 2-Methoxyethanol.
6-Deoxyerythronolide BThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abatacept.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept.
AbetimusThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abetimus.
AbetimusThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910522
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceTuberculosis Infection1
0CompletedTreatmentBladder Cancers1
1CompletedTreatmentBladder Cancers1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentNeuroblastomas / Sarcomas1
1RecruitingTreatmentRecurrent Bladder Carcinoma / Stage 0a Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Cancer1
1Unknown StatusTreatmentTransitional Cell Carcinoma of Bladder1
1, 2Active Not RecruitingTreatmentBladder Cancers / High-Risk Non-Muscle-Invasive Bladder Cancer1
1, 2CompletedTreatmentColorectal Cancers1
1, 2Unknown StatusTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentBladder Cancers1
2CompletedNot AvailableBladder Cancers1
2CompletedTreatmentBladder Cancers3
2TerminatedTreatmentCancer of the Ovary1
2TerminatedTreatmentMelanoma (Skin)1
2Unknown StatusTreatmentProstate Cancer1
2, 3CompletedTreatmentSepsis1
3CompletedTreatmentBladder Cancers2
3CompletedTreatmentColorectal Cancers1
3CompletedTreatmentLung Cancers2
3Not Yet RecruitingTreatmentBladder Cancers1
3RecruitingTreatmentHigh-risk Non-muscle Invasive Bladder Cancer1
3RecruitingTreatmentStage 0 Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Urothelial Carcinoma1
3TerminatedTreatmentBladder Cancers1
4Active Not RecruitingBasic ScienceWhooping Cough1
4CompletedPreventionBCG Infection / Immune Response / Reaction - Vaccine1
Not AvailableCompletedBasic ScienceBCG Vaccination1
Not AvailableCompletedBasic ScienceInnate Immune Response1
Not AvailableNot Yet RecruitingPreventionBCG Vaccination Reaction1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionPercutaneous50 mg/1
Powder, for solutionIntravesical800000000 unit
Powder, for suspensionIntravesical50 mg/50mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:03 / Updated on January 22, 2019 17:57